A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00136942
First received: August 25, 2005
Last updated: February 28, 2008
Last verified: April 2007
  Purpose

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.


Condition Intervention Phase
Hyperlipidemia
Drug: Atorvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcome Measures:
  • The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Estimated Enrollment: 370
Study Start Date: April 2005
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
  • LDL-C < 6.0 mmol/l
  • Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

  • Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00136942

Locations
Switzerland
Pfizer Investigational Site
Langenthal, BE, Switzerland
Pfizer Investigational Site
Thun, BE, Switzerland
Pfizer Investigational Site
Binningen, BL, Switzerland
Pfizer Investigational Site
Liestal, BL, Switzerland
Pfizer Investigational Site
Basel, BS, Switzerland
Pfizer Investigational Site
Duedingen, FR, Switzerland
Pfizer Investigational Site
Geneve, GE, Switzerland
Pfizer Investigational Site
Onex, GE, Switzerland
Pfizer Investigational Site
Pfaeffikon, SZ, Switzerland
Pfizer Investigational Site
Siebnen, SZ, Switzerland
Pfizer Investigational Site
Lugano, TI, Switzerland
Pfizer Investigational Site
Malvaglia, TI, Switzerland
Pfizer Investigational Site
Melide, TI, Switzerland
Pfizer Investigational Site
Vezia, TI, Switzerland
Pfizer Investigational Site
Ecublens, VD, Switzerland
Pfizer Investigational Site
Lausanne, VD, Switzerland
Pfizer Investigational Site
Prilly, VD, Switzerland
Pfizer Investigational Site
Unteraegeri, ZG, Switzerland
Pfizer Investigational Site
Zug, ZG, Switzerland
Pfizer Investigational Site
Zuerich, ZH, Switzerland
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00136942     History of Changes
Other Study ID Numbers: A2581089
Study First Received: August 25, 2005
Last Updated: February 28, 2008
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 21, 2014